When a talar cartilage lesion needs an allograft

An ankle scan showing a cartilage defect on the talus — the domed bone that forms the foot's side of the ankle joint — raises an immediate question: is surgery actually needed, and if so, what kind? For most people, the answer depends less on the scan finding alone and more on the size of the damage, whether the underlying bone is involved, and what has already been tried.

Talar cartilage injuries, known as osteochondral lesions of the talus (OLT), are more common than many patients realise. Up to 50% of ankle sprains and over 70% of ankle fractures are associated with this type of damage, which is why the typical person seeking treatment is a young or middle-aged active adult rather than someone approaching joint replacement age.

Osteochondral allograft (OCA) transplantation sits at the cartilage-restoration stage of the treatment ladder — not a first step, but an option that becomes relevant when conservative care and smaller procedures cannot achieve a durable result. Rather than stimulating the body to fill the gap with scar-like fibrocartilage, OCA replaces the damaged surface with fresh donor tissue: a plug of real bone topped by intact hyaline cartilage, shaped and fitted to the defect in a single operation. This distinction matters — the graft restores the structural layer that load-bearing demands, rather than patching it.

Lesion size, failed surgery, and other eligibility factors

Whether OCA is appropriate comes down to three interlocking questions: how large is the defect, how deep does it go, and what has already been tried?

Lesion size is the most cited threshold. Bone marrow stimulation techniques such as microfracture — where small perforations encourage a fibrocartilage repair response — produce reasonable results when the average lesion diameter stays below roughly 15 mm (approximately 150 mm²). Above that threshold, the evidence essentially collapses: in published series, only around 3% of patients with lesions at or beyond 15 mm achieved a successful outcome with microfracture alone. The structural gap is simply too large for marrow-derived repair cells to fill reliably.

Prior microfracture also affects eligibility in a different way. Repeated drilling can damage the subchondral bone plate — the load-bearing layer beneath the cartilage — which limits what scaffold-based techniques can achieve later. Significant subchondral involvement, such as a cyst or early collapse, further narrows the options: surface-only repairs cannot address bone-level structural failure, whereas OCA replaces both layers simultaneously.

OCA is not a treatment of last resort positioned just before ankle replacement. It is an active restoration procedure suited to specific structural criteria, and it makes most sense in patients who are still decades away from replacement candidacy. Published series illustrate the scale of defects being addressed: mean graft coverage in one large cohort reached 41.1% of the talar dome, confirming these are substantial structural problems, not minor blemishes a simpler technique would resolve.

What the operation involves

Three broad surgical approaches fall under the OCA umbrella, chosen according to the size and complexity of the defect rather than surgeon preference alone.

Gaining access to the talar dome

The talus sits deep inside the ankle joint, which means the surgeon first needs to create a clear working view before any graft can be placed. For lesions on the inner (medial) side, this involves a chevron-shaped cut through the medial malleolus — the bony prominence on the inner ankle — known as a medial malleolar osteotomy. Lateral lesions require a tibial trapezoidal osteotomy on the outer side. In both cases the bone is cut deliberately, held back to expose the talar surface, and then fixed back into its original position with screws at the end of the operation. The osteotomy is a planned step in the procedure, not a complication.

Standard OCA plug

For most patients, the surgeon removes the damaged cartilage and underlying bone with a cylindrical coring tool, then press-fits a matching cylindrical plug of fresh donor tissue — real bone topped by intact hyaline cartilage — into the prepared site. The tight fit stabilises the graft mechanically while biological incorporation takes place over subsequent months.

Hemitalus allograft for large or recurrent lesions

When the defect is very large or has already failed an earlier cartilage procedure, a standard plug may not cover the damaged area adequately. Hemitalus allograft transplantation replaces a greater portion of the talar dome using a larger segment of donor tissue. Published prospective data support this approach as safe and effective in this specific subgroup.

ARR for volumetric bone loss

Articular Regional Reconstruction (ARR) addresses cases where significant bone volume has been lost alongside the cartilage damage. The technique layers a viable osteochondral allograft sheet (Cartiform®), shaped to fit, over morselised autograft bone and secures it with suture anchors. It remains an emerging option for complex defects that exceed the depth or size limitations of a single plug.

Matching the donor graft

Whichever technique is used, graft congruency matters. Research indicates that articular length predicts the talar dome's radius of curvature more reliably than articular width or donor age, so surgeons use this measurement when selecting and shaping the allograft. A well-matched contour reduces the risk of a small height mismatch — known as articular step-off — at the graft edge.

What outcomes the evidence realistically supports

The strongest available long-term data comes from the 34-patient, 36-ankle case series with a mean follow-up of 9.2 years. Graft survivorship reached 94.3% at five years and 85.3% at ten years — figures that compare favourably with most cartilage restoration procedures and support OCA as a durable intervention for the right candidate. Patient satisfaction matched that profile: 79.4% reported being satisfied or extremely satisfied at long-term review.

Return to physical activity tells a more complex story. In that same cohort, 66.7% returned to sport or recreational activity at some point after surgery, but only 50% were still participating at the 9.2-year mark. The drop does not reflect graft deterioration — it mirrors the natural decline in activity levels over nearly a decade in a population that was already past peak sporting age at the time of surgery. Among competitive athletes and frequent sports participants, the picture held up better: 73.9% returned at some point, with 65.2% still active at latest follow-up.

A systematic review of 13 studies and 772 OCA patients reported a return-to-sport rate of 75–82%, broadly in line with the case series. The same review flagged a reoperation rate of 34–53%, which warrants careful reading. At follow-up periods under three years, the majority of these operations represent planned hardware removal — the screws placed during surgery to hold the osteotomised malleolus in position. That is a routine and anticipated step, not evidence of graft failure. True graft revision remains a distinct and less common event.

All of this evidence comes from case series — Level 4 in the research hierarchy — meaning no randomised trial has yet directly compared OCA with other cartilage restoration strategies for talar lesions. The outcomes are drawn from selected patients treated at specialist centres, a real constraint on how broadly the numbers translate to individual cases.

Recovery: the realistic timeline

Leaving the operating theatre, most patients will be on crutches — non-weight-bearing or partial-weight-bearing — for the first six to eight weeks. That protected phase gives the donor bone time to begin integrating with the host tissue; loading too early risks disrupting a biological process that unfolds on its own schedule.

Gentle range-of-motion exercises begin in the days immediately after surgery. Moving the ankle early keeps the joint from stiffening and supports cartilage nutrition without applying direct load to the graft. A physiotherapist typically guides progression through each stage of rehabilitation.

The broader recovery arc is measured in months rather than weeks. Low-impact activities — swimming, stationary cycling, walking on level ground — are reintroduced progressively once early incorporation is confirmed. Return to more demanding sport or physical work depends on the scale of the original defect, any concurrent procedures, and how the graft appears on follow-up imaging. Specialists set milestones individually rather than by fixed calendar targets; desk-based work and light daily tasks are usually achievable well before higher-impact demands.

Patients who underwent a malleolar osteotomy to access the talar dome should be aware before surgery that the fixation screws may be removed at a separate planned procedure once bone healing is confirmed. Factoring this into practical planning — including any anticipated time off work — is a straightforward pre-operative conversation, not an unexpected complication.

How OCA compares to alternatives and finding the right specialist

Deciding whether OCA is the right procedure requires placing it in context rather than treating it as a universal answer to talar cartilage damage.

For smaller lesions — those below roughly 150 mm² with intact subchondral bone — a surgeon may first discuss single-stage options such as AMIC (matrix-augmented microfracture) or OATS (osteochondral autograft transfer), which draw on the patient's own tissue and carry lower logistical demands. OCA becomes the preferred conversation when defects are larger, structurally complex, or when prior procedures have already failed.

OCA is not the same as particulated juvenile cartilage allograft

One distinction that patients may encounter when reading around the subject is between fresh bulk OCA and particulated juvenile cartilage allograft (PJCA) — a different product entirely. A systematic review of 241 patients treated with PJCA for OLT recorded a 25.2% complication rate, a 12.4% short-term failure rate at a mean of 9.8 months, and poor MOCART scores; the authors concluded it cannot be recommended for large talar lesions. The long-term survivorship data discussed earlier in this article relates specifically to fresh bulk OCA, not to PJCA.

Individual factors still matter

Several outcome-modifying variables — including BMI, concurrent ankle instability, immune response, and the mechanical fit of the graft — are recognised in the literature but have not yet been combined into a validated risk-stratification tool for the ankle. Patients should raise their individual profile with their specialist rather than mapping population-level figures directly onto their own situation.

OCA also requires specialist infrastructure: fresh allograft procurement, processing, and size-matching are not available at every orthopaedic unit, and identifying a surgeon with relevant experience in talar cartilage restoration is a practical step in the pathway.